Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1463 other investors.
Redeye returns with a follow-up note to Genovis’ Q2’21 report and continues to have a positive long-term view of the case.
Redeye regards Genovis’ Q2’21 report as solid and finds it encouraging to see continued high growth in the core Analytics segment.
In this note, Redeye elaborates on why we see the cross-licensing agreement with GlycoT Therapeutics as strategically interesting.
Redeye provides a follow-up note to Genovis Q1'21 report, with updated estimates and valuation.
Redeye’s first impression of Genovis Q1’21 is that it is a pretty solid report in the core business, given that customer activity remains regionally sluggish due to the pandemic.